Abstract

IN recent years, there have been important advances in our understanding of the biology of bladder cancer. They have been achieved with the use of new experimental models, the study of oncogenes in bladder cancer, and the demonstration of a wide range of functional heterogeneity in populations of morphologically identical bladder cancer cells. The development of new techniques of management — including diagnosis and staging, the use of intravesical chemotherapy and preemptive (neoadjuvant) intravenous chemotherapy, and the application of new monoclonal antibodies — appears to be yielding higher rates of response, prolonged disease-free survival, and perhaps even improved rates of . . .

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.